Delcath Systems is an interventional oncology company that deals with primary and metastatic liver cancers in Europe and the United States. The company has a clinical development strategy for HEPZATO, its lead product, which is a melphalan hydrochloride for injection/hepatic delivery system that administers high-dose chemotherapy to the liver while minimizing systemic exposure and related side effects. The company also sells HEPZATO as a standalone medical device known as the CHEMOSAT Hepatic Delivery System for Melphalan to healthcare centers in Europe.